On May 14, 2020 Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic and other major diseases, reported that clinical data on its ORIENT-2 study of TYVYT (sintilimab injection), an innovative anti-PD-1 antibody co-developed with Eli Lilly and Company, in patients with advanced or metastatic esophageal squamous cell carcinoma will be presented by poster discussion, and six other clinical studies will be presented as posters or online publications at the 56th American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Innovent Biologics, MAY 14, 2020, View Source [SID1234558082]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Discussion
Title:
Sintilimab in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma Refractory to Previous Chemotherapy: A Randomized, Open-Label Phase 2 Study (ORIENT-2)
Abstract ID: 4511
Poster ID: 119
Session:
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
First Author:
Jianming Xu, MD (The Fifth Medical Center of PLA General Hospital)
Poster
Title:
Phase 1a Dose Escalation of IBI318, a First-in-Class Bispecific Anti-PD-1/PD-L1, in Patients with Advanced Tumors
Abstract ID: 3062
Poster ID: 126
Session:
Developmental Therapeutics-Immunotherapy
First Author:
Ruihua Xu, MD (Sun Yat-sen University Cancer Center)
Title:
Preliminary Results of Sintilimab Plus Different Dose of IBI305 (anti-VEGF Monoclonal Antibody) in Patients with Advanced Hepatocellular Carcinoma: A Phase 1b Study
Abstract ID: 3079
Poster ID: 143
Session:
Developmental Therapeutics-Immunotherapy
First Author:
Wen Zhang, MD (Cancer Hospital, Chinese Academy of Medical Sciences)
Title:
Sintilimab for Relapsed/Refractory Classical Hodgkin’s Lymphoma: Long-Term Follow-up on the Multicenter, Single-Arm Phase 2 ORIENT-1 Study
Abstract ID: 8034
Poster ID: 367
Session:
Hematologic Malignancies–Lymphoma and Chronic Lymphocytic Leukemia
First Author:
Hang Su, MD (The Fifth Medical Center of PLA General Hospital)
Title:
Sintilimab for Relapsed/Refractory (r/r) Extranodal NK/T Cell Lymphoma (ENKTL): Extended Follow-up on the Multicenter, Single-Arm Phase 2 Study (ORIENT-4)
Abstract ID: 8050
Poster ID: 383
Session:
Hematologic Malignancies–Lymphoma and Chronic Lymphocytic Leukemia
First Author:
Jianyong Li, MD, PhD (Jiangsu Province Hospital)
Online Publication
Title:
IBI310 Monotherapy or in Combination with Sintilimab in Patients with Advanced Melanoma: An Open-Label Phase 1a/1b Study
Abstract ID: 302489
First Author:
Bin Lian, MD (Beijing Cancer Hospital)
Title:
Transarterial Infusion Chemotherapy (TAI) Combined with Sintilimab in Locally Advanced, Potentially Resectable Hepatocellular Carcinoma (HCC)
Abstract ID: e16593
First Author:
Li Xu, MD (Sun Yat-sen University Cancer Center)